Celia banks q&a


Published on

Published in: Education
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Celia banks q&a

  1. 1. Do You Know Enough About ISO 26000:2010 Guidance on Social Responsibility? Celia Banks, Continuous Improvement Lead for Pfizer Worldwide R&D Business Technology, speaks to Garry Lambert, a Switzerland based freelance journalist, about how Pfizer is implementing ISO 26000:2010, Guidance on Social Responsibility, published by the International Organization for Standardization, which has been designed for implementation by all types of organization regardless of size or location, with the intention of helping them contribute to sustainable development.Biography• Celia Banks joined Pfizer in 2010 to lead the Worldwide Research & Development Business Technology Continuous Improvement and Learning & Development Program. Her role also supports Medical Business Technology• Prior to joining Pfizer as a colleague, worked as a contractor with Pfizer in Research & Development and Medical Informatics, where she helped establish the CI Program employing a bottom-up approach initially and has matured the program to be leadership driven• Prior to Pfizer, was contracted by Toyota Motor Sales as Program Manager for the Discovery phase of the Vehicle Supply Chain Renovation• Possesses a philosophical doctorate in Human and Organization Systems; a Masters in Organization Development; a Masters in Administrative Management; and a Masters in Applied Statistics. She is certified by the American Society of Quality as a Quality Manager in Organizational Excellence and by Villanova University as a Six Sigma Black BeltQ&AG Lambert: Could you outline how Pfizer is implementing the guidance in ISO 26000?C Banks: At Pfizer, Corporate Responsibility is the ‘how” of how we do business. We supportcomprehensive strategies across our operations to ensure best-in-class performance in CR. We useseveral frameworks to guide our CR strategy—including ISO 26000, the Global Reporting Initiative (GRI)and the UN Global Compact.Pfizer is a proud member of the UN Global Compact (UNGC) which is a framework for businesses thatare committed to aligning their operations with universally accepted principles in human rights, labor,environmental performance and anti-corruption. Pfizer was the first US pharmaceutical company to signthe UNGC in 2002 and has remained an active participant. We were also one of the first US companiesto join the Compact, and helped encourage other large US-based multi-nationals to participate.Pfizer is also a signatory to the UN Caring for Climate Initiative, a complementary platform for UNGCparticipants who seek to demonstrate leadership on climate change. Pfizer Joined in 2007.At Pfizer, we work every day to address social issues such as access to medicine by partnering withothers to invest the full range of our resources—people, skills, expertise and funding—to improve global
  2. 2. health. Our philanthropic platform, Pfizer Investments in Health, invests resources through a coordinatedapproach that contributes to society through medicine access and health care system strengtheningThe Global Health Fellows program (GHF) is one example of this work. GHF is an international corporatevolunteer program that places Pfizer colleagues in three to six month assignments with internationaldevelopment organizations designed to address global health issues and improve care for underservedpopulations. During assignments fellows transfer their professional, medical and business expertise inways that promote access, quality and efficiency of health care services.We do what we say we will in supporting our CSR culture. Just recently the Pichincha provincialgovernment awarded Pfizer Ecuador the first place General Rumiñahui prize for excellence in itscorporate responsibility programs.[Photo: Pfizer Ecuador CSR Award]Regarding environmental sustainability, our Pfizer Global Supply facility in Freiburg, Germany was namedFacility of the Year 2011 by the International Society for Pharmaceutical Engineering. Oh, and by theway, the recognition represents the second time in three months that the plant was acknowledged for itssustainable drug production practices. The facility also received the state of Baden-Württemberg’sEnvironmental award for industrial environmental protection and corporate governance.[Photo: Freiburg Facility]We aim to be a leader in public reporting and transparent disclosure of our CR performance. This is thefirst year that we combined our annual and corporate responsibility reports into a single entity known in
  3. 3. the investor community as “one report.” The inclusion of social, governance and environmentalperformance in a single company report alongside business and financial data is a growing trend.Increasingly investors and other stakeholders seek information that captures a comprehensive view of acompany’s performance, including financial and non-financial metrics. We are proud of thisaccomplishment. The report can be found at www.pfizer.com/annual.G Lambert: Have ISO 26000 guidelines caused your company to change/adapt its sustainabledevelopment principles and practices – if so, how?C Banks: This is sort of a horse before the cart question, or vice versa. Our CR efforts are built on a longhistory of ethical business practices and social responsibility. The ISO 26000 standard is new in the CRfield but incorporates many elements that are core to our CR strategy and reporting, so there is clearalignment. In the pure sense, if I looked at it from a timing perspective, then the answer is no.However, a different perspective of your question considers the connection of Continuous Improvementprograms to CR. A number of CI colleagues and I were formally introduced to ISO 26000 by RobertoSaco, a past president of the American Society of Quality. His challenge to us was that we drive CR intoour CI efforts.G Lambert: In the words of the standard, has it influenced the way you are ‘integrating, implementing andpromoting socially responsible behaviour throughout the organization’ - giving examples if possible?C Banks: We use global standards, like ISO, GRI and the UNGC, to inform our strategy and publicreporting. The fundamental elements of ISO link to core CR elements in corporate strategy.G Lambert: ISO 26000 is intended to encourage organizations to go beyond legal compliance – would itbe fair to say that the standard has encouraged Pfizer to do so in its socially responsible behaviour?C Banks: Pfizer has a long history of strong CR performance. The foundation of our CR activities isresponsible operations and we strive to meet or exceed legal requirements in the countries where we dobusiness—so this means ethics and compliance are cornerstones of our strategy. However in manyareas we look for innovative solutions to some of the most pressing social problems—which greatlyexceed any legal obligation.G Lambert: Has it influenced the way you engage with stakeholders, customers and suppliers, and doyou prefer/require suppliers to follow ISO 26000 guidance?C Banks: Strong stakeholder relationships, and meeting stakeholder expectations, are integral to oursuccess in CR. ISO guidance underscores the importance of those relationships. We work with ourstakeholders and suppliers to improve their CR capacity. For example, Pfizer is a founding member ofthe Pharmaceutical Supply Chain Initiative (PSCI) which seeks to implement standards in human rights,labor, environment and ethics through our supply chain.I read the ISO standard as follow up after the presentation that Roberto Saco provided. It causes me as aCI expert to stop and think about the improvements we apply including those that touch upon vendorrelations.G Lambert: Can you give examples of any benefits to Pfizer of ISO 26000 implementation - e.g. inhelping drive continuous improvement and operational excellence, etc?C Banks: One example I know first-hand shaped the desire of a colleague to do a Lean Green Beltproject for improving conference room lighting. The improvement did not focus on using brighter wattbulbs, but rather on energy efficient lighting.
  4. 4. G Lambert: Are there any further comments you might wish to make about the standard – its suitabilityand applicability, how it could be improved, etc., and perhaps any advice you might give to othercompanies considering ISO 26000 implementation?C Banks: Sure, I encourage all of those involved in CI to be social change agents. All companies shouldseek opportunities to drive continuous improvement, and their CR activities should be no exception.Stronger CR performance helps to advance Pfizer’s business success and to meet evolving the evolvingstakeholder expectations that we face as a global pharmaceutical company.Celia Banks will be speaking at the Business Process Excellence for Pharmaceuticals, Biotech andMedical Devices Conference 2011, which will take place from April 7th-8th at The Brewery, London. Forfurther information please visit www.bpe-pharma.com, call 0800 652 2363 or email enquire@iqpc.co.uk.If you would like to learn more on the subject, you may be interested in attending Lean Leaders, themeeting for senior business leaders who want to drive their Lean programmes to the next level. Throughinteractive leader-to-leader discussions, over two days you will learn, share and network with leadingadvocates of Lean from world-class operational excellence organisations.